Hammerman A, Moore CM, Aboalhasan E, Azuri J, et al. Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus. Am J Cardiol 2022 Feb 20. pii: S0002-9149(22)00093.
PMID: 35197207